Vivos Therapeutics (VVOS) Total Debt (2019 - 2026)

Vivos Therapeutics (VVOS) posted quarterly Total Debt of $7.7 million for Q1 2026, down 12.53% quarter-over-quarter from $8.8 million in Q4 2025.

Vivos Therapeutics (VVOS) Total Debt (2019 - 2026) Analysis & Trends

Vivos Therapeutics (VVOS) has reported Total Debt for 5 consecutive years, with $7.7 million the latest figure, recorded in Q1 2026.

In Q1 2026, Total Debt changed N/A year-over-year to $7.7 million; the TTM figure through Mar 2026 stood at $7.7 million (changed N/A YoY), while the FY2025 annual figure was $8.8 million, changed N/A from the prior year.
Total Debt fell to $7.7 million in Q1 2026 per VVOS's latest filing, from $8.8 million in the prior quarter.
Across five years, Total Debt topped out at $8.8 million in Q4 2025 and bottomed at $7.7 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Abbott Laboratories	200.51 Bn	194.90 Bn	7.27 Bn	32.61 Bn
2	Stryker	126.12 Bn	122.64 Bn	4.50 Bn	14.94 Bn
3	Medtronic	118.45 Bn	109.23 Bn	6.41 Bn	27.96 Bn
4	Boston Scientific	73.30 Bn	72.77 Bn	3.85 Bn	12.62 Bn
5	Edwards Lifesciences	51.60 Bn	47.35 Bn	1.35 Bn	598.70 Mn
6	Dexcom	34.52 Bn	32.57 Bn	830.00 Mn	-
7	GE HealthCare Technologies	33.71 Bn	31.60 Bn	2.18 Bn	10.10 Bn
8	Koninklijke Philips	26.14 Bn	22.82 Bn	4.55 Bn	8.68 Bn
9	Steris	23.13 Bn	22.65 Bn	684.20 Mn	1.89 Bn
10	Vivos Therapeutics	4.96 Mn	3.16 Mn	2.95 Mn	8.14 Mn

Download Data